Abstract:The study by Wagner et al. (https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1416319/full) employs advanced imaging techniques to visualize clot structures in extracorporeal membrane oxygenation (ECMO) devices, revealing the importance of platelet-leukocyte aggregates and von Willebrand factor in clot stability and dissolution. This work underscores the dynamic nature of thrombus formation, where mechanical forces and cellular components interact to influence clot architecture and stability. Similarly, the research by Yuan et al. (https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1165589/full) delves into the role of Toll-like receptor 4 (TLR4) in thrombus resolution, highlighting the receptor's involvement in mediating inflammatory responses necessary for thrombus breakdown. In recent years, extensive research has explored the link between inflammation and thrombosis, revealing that the immune and coagulation systems are functionally interconnected (5). The study demonstrates that TLR4 deficiency impairs thrombus resolution in a mouse model, emphasizing the importance of inflammation and immune signaling in the clearance of thrombi. This finding aligns with the broader understanding that thrombosis is not merely a hemostatic event but also an inflammatory process, where immune cells and cytokines play pivotal roles (6)(7)(8)(9).A review by Khattak et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2024.1287553/full) further underscores the complex role of platelets in microvascular thrombosis during ST-elevation myocardial infarction (STEMI). The authors discuss how platelets, beyond their hemostatic function, contribute to inflammatory processes and microvascular obstruction, complicating recovery after myocardial infarction. Despite the widespread use of dual antiplatelet therapy, its effect on microvascular thrombosis remains unclear, driving the need for novel therapies targeting specific platelet receptors such as GPVI and PAR4. These emerging treatments show promise in mitigating microvascular damage with a lower risk of bleeding complications, offering new avenues for enhancing therapeutic strategies in STEMI management.The interplay between coagulation, inflammation and oxidative stress is further explored in the review by Bettiol et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1325002/full), which examines the regulatory role of SIRT1 in thrombosis. SIRT1, a NAD+-dependent deacetylase, modulates key processes such as endothelial activation, platelet aggregation, and inflammatory response, thereby influencing thrombus formation and stability. This review puts SIRT1 as a potential therapeutic target, suggesting that modulating its activity could offer new avenues for preventing and treating thrombotic diseases.While these studies focus on the molecular and cellular underpinnings of thrombosis, other contributions in this collection address the clinical implications of these mechanisms. Wu et al.'s multicenter retrospective cohort study (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1373635/full) evaluates the efficacy and safety of direct oral anticoagulants (DOACs) compared to low-molecularweight heparin (LMWH) in preventing venous thromboembolism in hospitalized cancer patients. The results suggest that DOACs may offer a safer and more effective alternative to traditional therapies, highlighting the need for personalized treatment approaches based on a deeper understanding of the patient's thrombotic risk profile and the molecular characteristics of their condition.Moreover, the impact of novel therapeutic strategies on thrombosis is exemplified in the study by Rodenas et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1182925/full), which investigates the use of venetoclax, a potent hepsin inhibitor, to reduce the metastatic and prothrombotic phenotypes of colorectal cancer cells. This research bridges the gap between oncology and thrombosis (10), demonstrating how targeted therapies can simultaneously address tumor progression and thrombotic risk, reflecting the interconnected nature of these pathophysiological processes.Collectively, the articles published in this Research Topic highlight the complexity of thrombosis as a multifaceted process involving hemostatic, inflammatory, and immune mechanisms. They also emphasize the potential of targeted therapies that go beyond traditional anticoagulation to modulate specific molecular pathways involved in thrombosis. As our knowledge of the molecular mechanisms underlying thrombosis advances, these studies offer a critical foundation for developing more targeted and effective therapeutic strategies, which will ultimately enhance patient outcomes and alleviate the public health burden of thr -Abstract Truncated-

Thrombin and Thrombin‐Incorporated Biomaterials for Disease Treatments

Cutting-edge advances in nano/biomedicine: A review on transforming thrombolytic therapy

Targeting Recombinant Thrombomodulin Fusion Protein to Red Blood Cells Provides Multifaceted Thromboprophylaxis

Thrombolysis of plasmin and its derivatives:research advances

The Research Progress of Direct Thrombin Inhibitors

Research Progress on Thrombin Inhibitor

DNA Nanotechnology in Molecular Design of Thrombin Aptamers

Editorial: Molecular mechanisms of thrombosis

Peptide-based targeting: Novel concept for thrombosis diagnosis and treatment

Discovering peptide inhibitors of thrombin as a strategy for anticoagulation

Direct thrombin inhibitors: patents 2002-2012 (Review).

Blood Compatible Materials: State of the Art.

Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding

Development of the Basic and Clinical Study of New Thrombolytic Drugs

An Update on Safe Anticoagulation.

Regulation of thrombin activity with a bifunctional aptamer and hemin: development of a new anticoagulant and antidote pair.

Preparation and Application of Quick Hemostatic Gauze Based on Biomimetic Mineralized Thrombin

Application of nanotechnology in thrombus therapy

Mechanisms of thrombosis and research progress on targeted antithrombotic drugs

Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis

Harnessing the power of bioprinting for the development of next-generation models of thrombosis